The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.

中文翻译：

---

PHOENIX 崛起：基于基因组的弥漫性大 B 细胞淋巴瘤疗法

弥漫性大 B 细胞淋巴瘤的分子分类为靶向致癌驱动通路和可操作突变的精准医学铺平了道路。在本期《癌细胞》中， Wilson 等人。执行大规模基因组分析，以确定与依鲁替尼加 R-CHOP 的差异反应相关的推定分子特征。